Pembrolizumab for Breast Cancer
This trial is testing a new cancer treatment involving two drugs. It will study the side effects and if the drugs are effective in treating triple-negative breast cancer.
- Triple Negative Breast Cancer
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2021 Phase 3 trial • 453 Patients • NCT03066778
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
What are some of the conditions that Pembrolizumab has been proven to be an effective treatment for?
What are we hoping to learn or achieve from this research?
"The purpose of this study, as it will be evaluated over a 10 month period, is to establish the adverse event rate. Additionally, the trial will secondary measure progress-free survival (PFS), overall survival (OS), and disease control rate (DCR)."
Are there any open spots left in this trial for new patients?
"Yes, the latest information available on clinicaltrials.gov indicates that this study is still recruiting patients. The study was first posted on February 27th, 2018 and was last updated on October 28th, 2020. A total of 211 participants are needed, and so far 24 sites have agreed to take part."
Are there similar ongoing Pembrolizumab trials elsewhere?
"City of Hope first researched pembrolizumab in 2010 and there have been 248 trials completed as of now. 1003 additional studies are still active, with a significant portion being conducted in Minneapolis, Minnesota."